We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The judge dismissed the remaining claims, saying they did not meet the threshold for whistleblower lawsuits as they cited third-party sources. Read More
The FDA Antimicrobial Drugs Advisory Committee voted 15-0 that Achaogen’s NDA for plazomicin proved safety and effectiveness for complicated urinary tract infections in patients with limited or no treatment options. Read More
The FDA finalized guidance on assessing user fees under PDUFA VI — covering fiscal years 2018 through 2022 — describing the new fee structure and the types of fees organizations are responsible for under the act. Read More
The agency noted that Health Canada-implemented ICH guidances take precedence over its existing guidances and said it is working to remove any inconsistencies. Read More
The U.S. Patent Trial and Appeal Board ruled in February 2017 that CRISPR patents granted to the Broad Institute for use in eukaryotic cells would stand. Read More
In the latest tussle over lucrative patents covering the revolutionary gene-editing technology CRISPR-Cas9, an appeals judge for the U.S. Court of Appeals for the Federal Circuit said she would likely side with the Broad Institute. Read More
In what Regeneron CEO Len Schleifer called a “paradigm-shifting agreement,” Sanofi and Regeneron sealed a deal with the pharmacy benefit manager Express Scripts cutting the price of their cholesterol drug Praulent (alirocumab) by up to $10,000 a year in exchange for easier access for Express Scripts patients. Read More
The medication-assisted treatments will be compared to a tentative list of medications commonly used in MAT, such as methadone, Vivitrol and Suboxone. Read More